Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
Journal website https://www.jofem.org |
Original Article
Volume 11, Number 2, April 2021, pages 42-48
The Significance of Insulin Resistance in Nondiabetic Breast Cancer Patients
Tables
Control group (n = 60) | Breast cancer (n = 80) | P | |
---|---|---|---|
BMI: body mass index; FBG: fasting blood glucose; FIL: fasting insulin level; HbA1c: hemoglobin A1c; HOMA-IR: homeostasis model assessment-insulin resistance; TNM: tumor-node-metastasis; ER: estrogen receptor; PR: progesterone receptor; HER-2/neu: human epidermal growth factor receptor-2. | |||
Age (years) | 49.8 ± 11.5 | 50.4 ± 12.5 | 0.750 |
BMI (kg/m2) | 25.67 ± 1.43 | 25.79 ± 1.48 | 0.567 |
FIL (mIU/L) | 7.1 ± 1.7 | 16.5 ± 3.7 | < 0.001 |
FBG (mg/dL) | 89.9 ± 8.5 | 93.8 ± 10.3 | 0.099 |
HbA1c (%) | 5.3 ± 0.4 | 5.2 ± 0.3 | 0.815 |
HOMA-IR | 1.57 ± 0.45 | 4.81 ± 1.19 | < 0.001 |
TNM | |||
1 | 8 (10) | ||
2 | 23 (28.7) | ||
3 | 22 (27.5) | ||
4 | 27 (33.8) | ||
ER | |||
Negative | 28 (35) | ||
Positive | 52 (65) | ||
PR | |||
Negative | 44 (55) | ||
Positive | 36 (45) | ||
HER-2 | |||
Negative | 61 (76.3) | ||
Positive | 19 (23.8) | ||
Classification | |||
Triple (-) | 3 (3.8) | ||
Luminal | 46 (57.5) | ||
HER-2 (+) | 19 (23.8) | ||
Triple (+) | 12 (15) |
Control group | Breast cancer | |||||
---|---|---|---|---|---|---|
Premenopause (n = 30) | Menopause (n = 30) | P | Premenopause (n = 40) | Menopause (n = 40) | P | |
Comparison with control group, *P < 0.001. BMI: body mass index; FBG: fasting blood glucose; FIL: fasting insulin level; HbA1c: hemoglobin A1c; HOMA-IR: homeostasis model assessment-insulin resistance. | ||||||
Age (years) | 39.1 ± 3.1 | 60.5 ± 4.5 | < 0.001 | 38.9 ± 4.0 | 61.9 ± 5.4 | < 0.001 |
BMI (kg/m2) | 25.46 ± 1.24 | 25.88 ± 1.57 | 0.501 | 25.76 ± 1.46 | 25.82 ± 1.50 | 0.558 |
FIL (mIU/L) | 7.1 ± 1.5 | 7 ± 1.8 | 0.992 | 16.8 ± 3.9* | 16.2 ± 3.4* | 0.712 |
FBG (mg/dL) | 88.3 ± 18.6 | 91.7 ± 8.5 | 0.875 | 90.2 ± 9.8 | 95.6 ± 11.2 | 0.546 |
HbA1c (%) | 5.2 ± 0.4 | 5.4 ± 0.3 | 0.752 | 5.1 ± 0.4 | 5.3 ± 0.3 | 0.999 |
HOMA-IR | 1.54 ± 0.48 | 1.59 ± 0.43 | 0.788 | 4.81 ± 1.18* | 4.82 ± 1.21* | 0.995 |
Sensitivity (%) | Specificity (%) | AUC | Cutoff | P | |
---|---|---|---|---|---|
FIL: fasting insulin level; HOMA-IR: homeostasis model assessment-insulin resistance; AUC: area under the curve. | |||||
FIL (mIU/L) | 98.8 | 82.7 | 0.987 | 8.5 | < 0.001 |
HOMA-IR | 97.5 | 96.7 | 0.998 | 2.4 | < 0.001 |
TNM | P | ||||
---|---|---|---|---|---|
1 | 2 | 3 | 4 | ||
FIL: fasting insulin level; HOMA-IR: homeostasis model assessment-insulin resistance; TNM: tumor-node-metastasis. | |||||
FIL (mIU/L) | 10.3 ± 1.4 | 14.9 ± 3.4 | 17.4 ± 2.2 | 19 ± 2.2 | < 0.001 |
HOMA-IR | 2.7 ± 0.4 | 4.1 ± 0.7 | 5.1 ± 0.7 | 5.9 ± 0.6 | < 0.001 |
PR (-), (n = 44) | PR (+), (n = 36) | P | |
---|---|---|---|
FIL: fasting insulin level; HOMA-IR: homeostasis model assessment-insulin resistance; ER: estrogen receptor; PR: progesterone receptor; HER-2/neu: human epidermal growth factor receptor-2. | |||
FIL (mIU/L) | 16.3 ± 3.9 | 16.7 ± 3.4 | 0.645 |
HOMA-IR | 4.8 ± 1.3 | 4.9 ± 1.1 | 0.616 |
ER (-), (n = 28) | ER (+), (n = 52) | P | |
FIL (mIU/L) | 16.7 ± 3.8 | 16.4 ± 3.6 | 0.767 |
HOMA-IR | 4.9 ± 1.2 | 4.8 ± 1.2 | 0.556 |
HER-2 (-), (n = 61) | HER-2 (+), (n = 19) | P | |
FIL (mIU/L) | 16.2 ± 3.6 | 17.6 ± 3.8 | 0.127 |
HOMA-IR | 4.7 ± 1.2 | 5.2 ± 1.1 | 0.115 |